{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:55:36Z","timestamp":1782302136112,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13300-021-01083-1","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T12:02:43Z","timestamp":1622030563000},"page":"2101-2113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03313752","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-1534","authenticated-orcid":false,"given":"Gian Pio","family":"Sorice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-7055","authenticated-orcid":false,"given":"Francesca","family":"Cinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-2898","authenticated-orcid":false,"given":"Lucia","family":"Leccisotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-8330","authenticated-orcid":false,"given":"Domenico","family":"D\u2019Amario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7867-2777","authenticated-orcid":false,"given":"Margherita","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-5088","authenticated-orcid":false,"given":"Maria Angela","family":"Guzzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-9576","authenticated-orcid":false,"given":"Teresa","family":"Mezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-6194","authenticated-orcid":false,"given":"Camilla","family":"Cocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8048-8664","authenticated-orcid":false,"given":"Umberto","family":"Capece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-022X","authenticated-orcid":false,"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-8846","authenticated-orcid":false,"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-0880","authenticated-orcid":false,"given":"Alessandro","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-7074","authenticated-orcid":false,"given":"Patricia","family":"Iozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-7792","authenticated-orcid":false,"given":"Andrea","family":"Giaccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1083_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.5114\/aoms.2014.43748","volume":"10","author":"J Kasznicki","year":"2014","unstructured":"Kasznicki J, Drzewoski J. Heart failure in the diabetic population\u2014pathophysiology, diagnosis and management. Arch Med Sci. 2014;10:546\u201356.","journal-title":"Arch Med Sci"},{"key":"1083_CR2","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1007\/s00125-012-2631-0","volume":"55","author":"S Masi","year":"2012","unstructured":"Masi S, Lautamaki R, Guiducci L, et al. Similar patterns of myocardial metabolism and perfusion in patients with type 2 diabetes and heart disease of ischaemic and non-ischaemic origin. Diabetologia. 2012;55:2494\u2013500.","journal-title":"Diabetologia"},{"key":"1083_CR3","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.2337\/diabetes.51.10.3020","volume":"51","author":"P Iozzo","year":"2002","unstructured":"Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes. 2002;51:3020\u20134.","journal-title":"Diabetes"},{"key":"1083_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.CIR.93.4.737","volume":"93","author":"NV Marinho","year":"1996","unstructured":"Marinho NV, Keogh BE, Costa DC, Lammerstma AA, Ell PJ, Camici PG. Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation. 1996;93:737\u201344.","journal-title":"Circulation"},{"key":"1083_CR5","doi-asserted-by":"publisher","first-page":"H976","DOI":"10.1152\/ajpheart.00088.2002","volume":"283","author":"LM Semeniuk","year":"2002","unstructured":"Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db\/db and transgenic db\/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol. 2002;283:H976-982.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1083_CR6","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1210\/jc.2012-1219","volume":"97","author":"HR Lehto","year":"2012","unstructured":"Lehto HR, Parkka J, Borra R, et al. Effects of acute and one-week fatty acid lowering on cardiac function and insulin sensitivity in relation with myocardial and muscle fat and adiponectin levels. J Clin Endocrinol Metab. 2012;97:3277\u201384.","journal-title":"J Clin Endocrinol Metab"},{"key":"1083_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00592-014-0695-7","volume":"52","author":"A Salerno","year":"2015","unstructured":"Salerno A, Fragasso G, Esposito A, et al. Effects of short-term manipulation of serum FFA concentrations on left ventricular energy metabolism and function in patients with heart failure: no association with circulating bio-markers of inflammation. Acta Diabetol. 2015;52:753\u201361.","journal-title":"Acta Diabetol"},{"key":"1083_CR8","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1161\/CIRCULATIONAHA.106.645184","volume":"114","author":"H Tuunanen","year":"2006","unstructured":"Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006;114:2130\u20137.","journal-title":"Circulation"},{"key":"1083_CR9","doi-asserted-by":"publisher","first-page":"e53247","DOI":"10.1371\/journal.pone.0053247","volume":"8","author":"R Nielsen","year":"2013","unstructured":"Nielsen R, Norrelund H, Kampmann U, Botker HE, Moller N, Wiggers H. Effect of acute hyperglycemia on left ventricular contractile function in diabetic patients with and without heart failure: two randomized cross-over studies. PLoS ONE. 2013;8:e53247.","journal-title":"PLoS ONE"},{"key":"1083_CR10","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00125-014-3307-8","volume":"57","author":"MA Guzzardi","year":"2014","unstructured":"Guzzardi MA, Hodson L, Guiducci L, et al. Independent effects of circulating glucose, insulin and NEFA on cardiac triacylglycerol accumulation and myocardial insulin resistance in a swine model. Diabetologia. 2014;57:1937\u201346.","journal-title":"Diabetologia"},{"key":"1083_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Investigators E-RO: empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1083_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1083_CR13","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:2099.","journal-title":"N Engl J Med"},{"key":"1083_CR14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","volume":"59","author":"N Sattar","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333\u20139.","journal-title":"Diabetologia"},{"key":"1083_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420\u20138.","journal-title":"Diabetes Care"},{"key":"1083_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/dom.12322","volume":"16","author":"S Sha","year":"2014","unstructured":"Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087\u201395.","journal-title":"Diabetes Obes Metab"},{"key":"1083_CR17","doi-asserted-by":"crossref","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981\u201397.","DOI":"10.1001\/jama.288.23.2981"},{"key":"1083_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"1083_CR19","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: a \u201cThrifty Substrate\u201d Hypothesis. Diabetes Care. 2016;39:1108\u201314.","journal-title":"Diabetes Care"},{"key":"1083_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A Unifying Hypothesis. Diabetes Care. 2016;39:1115\u201322.","journal-title":"Diabetes Care"},{"key":"1083_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","volume":"24","author":"GD Lopaschuk","year":"2016","unstructured":"Lopaschuk GD, Verma S. Empagliflozin\u2019s fuel hypothesis: not so soon. Cell Metab. 2016;24:200\u20132.","journal-title":"Cell Metab"},{"key":"1083_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","volume":"133","author":"G Aubert","year":"2016","unstructured":"Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698\u2013705.","journal-title":"Circulation"},{"key":"1083_CR23","doi-asserted-by":"crossref","unstructured":"Horton JL, Martin OJ, Lai L, et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight 2016;2(1):e84897.","DOI":"10.1172\/jci.insight.84897"},{"key":"1083_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI115008","volume":"87","author":"RR Russell 3rd","year":"1991","unstructured":"Russell RR 3rd, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest. 1991;87:384\u201390.","journal-title":"J Clin Invest"},{"key":"1083_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0300-2977(97)00012-0","volume":"50","author":"RA DeFronzo","year":"1997","unstructured":"DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med. 1997;50:191\u20137.","journal-title":"Neth J Med"},{"key":"1083_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1445-5994.1999.tb00754.x","volume":"29","author":"D Playford","year":"1999","unstructured":"Playford D, Watts GF. Endothelial dysfunction, insulin resistance and diabetes: exploring the web of causality. Aust N Z J Med. 1999;29:523\u201334.","journal-title":"Aust N Z J Med"},{"key":"1083_CR27","doi-asserted-by":"publisher","first-page":"E1163","DOI":"10.1152\/ajpendo.00386.2001","volume":"282","author":"P Iozzo","year":"2002","unstructured":"Iozzo P, Chareonthaitawee P, Di Terlizzi M, Betteridge DJ, Ferrannini E, Camici PG. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab. 2002;282:E1163-1171.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1083_CR28","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1161\/01.CIR.103.13.1734","volume":"103","author":"D Jagasia","year":"2001","unstructured":"Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation. 2001;103:1734\u20139.","journal-title":"Circulation"},{"key":"1083_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00125-016-4194-y","volume":"60","author":"R Vettor","year":"2017","unstructured":"Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017;60:395\u20138.","journal-title":"Diabetologia"},{"key":"1083_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"1083_CR31","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.2337\/diabetes.54.9.2787","volume":"54","author":"R Lautamaki","year":"2005","unstructured":"Lautamaki R, Airaksinen KE, Seppanen M, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes. 2005;54:2787\u201394.","journal-title":"Diabetes"},{"key":"1083_CR32","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration; Sarwar N, Gao P, et al.. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215\u201322.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"1083_CR33","doi-asserted-by":"crossref","unstructured":"IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes atlas: estimates for the year 2011. Diabetes Res Clin Pract 2013;100:277\u20139.","DOI":"10.1016\/j.diabres.2013.02.005"},{"key":"1083_CR34","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288\u201396.","journal-title":"Eur Heart J"},{"key":"1083_CR35","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1083_CR36","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1083_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117\u201328.","journal-title":"N Engl J Med"},{"key":"1083_CR38","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425\u201335.","journal-title":"N Engl J Med"},{"key":"1083_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207\u201358.","journal-title":"Physiol Rev"},{"key":"1083_CR40","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/CIRCHEARTFAILURE.112.000228","volume":"6","author":"L Zhang","year":"2013","unstructured":"Zhang L, Jaswal JS, Ussher JR, et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail. 2013;6:1039\u201348.","journal-title":"Circ Heart Fail"},{"key":"1083_CR41","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1210\/jc.2014-3472","volume":"100","author":"A Merovci","year":"2015","unstructured":"Merovci A, Mari A, Solis-Herrera C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100:1927\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"1083_CR42","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2337\/diacare.13.6.610","volume":"13","author":"L Rossetti","year":"1990","unstructured":"Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610\u201330.","journal-title":"Diabetes Care"},{"key":"1083_CR43","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care. 2019;42:931\u20137.","journal-title":"Diabetes Care"},{"key":"1083_CR44","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2337\/db20-0921","volume":"70","author":"KM Lauritsen","year":"2021","unstructured":"Lauritsen KM, Nielsen BRR, Tolbod LP, et al. SGLT2 inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a randomized double-blind placebo-controlled crossover trial. Diabetes. 2021;70:800\u20138.","journal-title":"Diabetes"},{"key":"1083_CR45","doi-asserted-by":"publisher","unstructured":"Oldgren J, Laurila S, Akerblom A, et al. Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a randomized, placebo-controlled, exploratory study. Diabetes Obes Metab. 2021. https:\/\/doi.org\/10.1111\/dom.14363.","DOI":"10.1111\/dom.14363"},{"key":"1083_CR46","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/dom.13814","volume":"21","author":"A Giaccari","year":"2019","unstructured":"Giaccari A. Sodium-glucose co-transporter inhibitors: medications that mimic fasting for cardiovascular prevention. Diabetes Obes Metab. 2019;21:2211\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1083_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229\u201334.","journal-title":"N Engl J Med"},{"key":"1083_CR48","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","volume":"103","author":"C Iribarren","year":"2001","unstructured":"Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668\u201373.","journal-title":"Circulation"},{"key":"1083_CR49","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","volume":"316","author":"RC Turner","year":"1998","unstructured":"Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823\u20138.","journal-title":"BMJ"},{"key":"1083_CR50","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group; Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","DOI":"10.1056\/NEJMoa1001286"},{"key":"1083_CR51","doi-asserted-by":"crossref","unstructured":"ADVANCE Collaborative Group; Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","DOI":"10.1056\/NEJMoa0802987"},{"key":"1083_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129\u201339.","journal-title":"N Engl J Med"},{"key":"1083_CR53","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/CIRCRESAHA.116.306206","volume":"118","author":"C Riehle","year":"2016","unstructured":"Riehle C, Abel ED. Insulin signaling and heart failure. Circ Res. 2016;118:1151\u201369.","journal-title":"Circ Res"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01083-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T19:49:30Z","timestamp":1667072970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01083-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01083-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}